Endolysin treatment against Staphylococcus aureus in adults with atopic dermatitis: A randomized controlled trial

J Allergy Clin Immunol. 2019 Sep;144(3):860-863. doi: 10.1016/j.jaci.2019.05.020. Epub 2019 May 27.

Authors

Jill de Wit¹, Joan E E Totté¹, Minke M F van Mierlo¹, Joyce van Veldhuizen¹, Martijn B A van Doorn¹, Frank H J Schuren², Sten P Willemsen³, Luba M Pardo¹, Suzanne G M A Pasmans⁴

Affiliations

¹ Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
² TNO, Microbiology and Systems Biology Group, Zeist, The Netherlands.
³ Department of Biostatistics, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
⁴ Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands. Electronic address: s.pasmans@erasmusmc.nl.

PMID: 31145938
DOI: 10.1016/j.jaci.2019.05.020

No abstract available

Publication types

Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Dermatitis, Atopic / drug therapy*
Double-Blind Method
Endopeptidases / therapeutic use*
Female
Humans
Male
Middle Aged
Recombinant Proteins / therapeutic use
Staphylococcal Infections / drug therapy*
Staphylococcus aureus*
Treatment Outcome
Young Adult

Substances

Recombinant Proteins
Endopeptidases
endolysin